Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Aug;118(8):2126–2130. doi: 10.1111/j.1476-5381.1996.tb15652.x

Characterization of [125I]-endothelin-1 and [125I]-BQ3020 binding to rat cerebellar endothelin receptors.

P S Widdowson 1, C N Kirk 1
PMCID: PMC1909893  PMID: 8864551

Abstract

1. We performed radioligand binding experiments on rat cerebellar homogenates using [125I]-endothelin-1 ¿[1251]-ET-1¿ and [125I]-BQ3020 to examine the pharmacology of endothelin receptors in rat brain. Saturation experiments demonstrated a single population of binding sites with high affinity for both radioligands ([125I]-ET-1, pKd = 8.94 +/- 0.17; [125I]-BQ3020, pKd = 9.18 +/- 0.14 nM; mean +/- s.e.mean). However, [125I]-BQ3020 only recognised approximately one third the number of endothelin receptors measured with [125I]-ET-1. 2. Saturation binding experiments with [125I]-PD151242 revealed high affinity binding to a single population of ETA receptors in the cerebellar homogenates (pKd = 9.95 +/- 0.14; Bmax = 30 +/- 15 fmol mg-1 protein). 3. Competition experiments were performed with ligands that are either non-selective for endothelin receptor subtypes. The rat cerebellar endothelin receptor displayed a high affinity for endothelin-1 (ET-1), endothelin-3 (ET-3) and sarafotoxin-S6c (STX-6c) although the affinity for ET-3 was slightly higher than the affinity for ET-1 using both radioligands. The selective ETA antagonists, BQ123, BMS-182,874 and JKC-301 all displayed low affinities at the endothelin receptors. In contrast the selective ETB agonists, IRL1620 and [Ala1,3,11,15]ET-1 and the selective ETB antagonist, BQ-788 had moderate affinities at the endothelin receptor, in the low nanomolar range. The ETB agonist, BQ3020, had approximately 10 fold higher affinity than IRL1620 and [Ala1,3,11,15]ET-1 at the rat cerebellar endothelin receptors. The non-selective antagonists, Ro-46,2005, Ro-47,0203 and PD-142,893 displayed moderate affinities at the cerebellar receptor. 4. Since [125I]-BQ3020 recognises only a fraction of the [125I]-ET-1 binding sites, the majority of the endothelin receptors in the cerebellum cannot be classed as ETB. Although [125I]-PD151242 was able to detect ETA receptors in the rat cerebellar homogenates, the small population of ETA receptors (2% of the total endothelin population as measured with [125I]-ET-1) could not account for the non-ETB receptor population. We conclude that the rat brain cerebellar receptor has a profile similar to the ETB1 receptor as it has a high affinity for ET-1, ET-3, STX-6c and was moderately sensitive to PD-142,893. However, as the ETB ligands BQ-788, IRL1620 and [Ala1,3,11,15]ET-1 have only a moderate affinity for the rat cerebellar endothelin receptor and since ET-3 has a higher affinity as compared to ET-1, our findings suggest that the rat cerebellum contains predominately ETc receptors.

Full text

PDF
2126

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Bax W. A., Saxena P. R. The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci. 1994 Oct;15(10):379–386. doi: 10.1016/0165-6147(94)90159-7. [DOI] [PubMed] [Google Scholar]
  3. Bousso-Mittler D., Galron R., Sokolovsky M. Endothelin/sarafotoxin receptor heterogeneity: evidence for different glycosylation in receptors from different tissues. Biochem Biophys Res Commun. 1991 Aug 15;178(3):921–926. doi: 10.1016/0006-291x(91)90979-h. [DOI] [PubMed] [Google Scholar]
  4. Breu V., Löffler B. M., Clozel M. In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993 Nov 15;334(2):210–214. doi: 10.1016/0014-5793(93)81713-a. [DOI] [PubMed] [Google Scholar]
  5. Buchan K. W., Alldus C., Christodoulou C., Clark K. L., Dykes C. W., Sumner M. J., Wallace D. M., White D. G., Watts I. S. Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors. Br J Pharmacol. 1994 Aug;112(4):1251–1257. doi: 10.1111/j.1476-5381.1994.tb13218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  7. Clozel M., Breu V., Gray G. A., Kalina B., Löffler B. M., Burri K., Cassal J. M., Hirth G., Müller M., Neidhart W. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994 Jul;270(1):228–235. [PubMed] [Google Scholar]
  8. Douglas S. A., Edwards R. M., Elliott J. D., Ohlstein E. H. In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670. Br J Pharmacol. 1995 Jan;114(2):405–413. doi: 10.1111/j.1476-5381.1995.tb13241.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Emori T., Hirata Y., Marumo F. Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett. 1990 Apr 24;263(2):261–264. doi: 10.1016/0014-5793(90)81388-5. [DOI] [PubMed] [Google Scholar]
  10. Gulati A., Rebello S. Characteristics of endothelin receptors in the central nervous system of spontaneously hypertensive rats. Neuropharmacology. 1992 Mar;31(3):243–250. doi: 10.1016/0028-3908(92)90174-n. [DOI] [PubMed] [Google Scholar]
  11. Hagiwara H., Nagasawa T., Yamamoto T., Lodhi K. M., Ito T., Takemura N., Hirose S. Immunochemical characterization and localization of endothelin ETB receptor. Am J Physiol. 1993 Apr;264(4 Pt 2):R777–R783. doi: 10.1152/ajpregu.1993.264.4.R777. [DOI] [PubMed] [Google Scholar]
  12. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863–2867. doi: 10.1073/pnas.86.8.2863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892–4896. doi: 10.1073/pnas.91.11.4892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jarvis M. F., Assal A. A., Gessner G. Pharmacological characterization of the rat cerebellar endothelin B (ETB) receptor using the novel agonist radioligand [125I]BQ3020. Brain Res. 1994 Nov 28;665(1):33–38. doi: 10.1016/0006-8993(94)91148-7. [DOI] [PubMed] [Google Scholar]
  15. Karne S., Jayawickreme C. K., Lerner M. R. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem. 1993 Sep 5;268(25):19126–19133. [PubMed] [Google Scholar]
  16. Lin H. Y., Kaji E. H., Winkel G. K., Ives H. E., Lodish H. F. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3185–3189. doi: 10.1073/pnas.88.8.3185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MacCumber M. W., Ross C. A., Snyder S. H. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2359–2363. doi: 10.1073/pnas.87.6.2359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Masaki T., Vane J. R., Vanhoutte P. M. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev. 1994 Jun;46(2):137–142. [PubMed] [Google Scholar]
  19. Nambi P., Pullen M., Feuerstein G. Identification of endothelin receptors in various regions of rat brain. Neuropeptides. 1990 Aug;16(4):195–199. doi: 10.1016/0143-4179(90)90062-4. [DOI] [PubMed] [Google Scholar]
  20. Nambi P., Pullen M., Spielman W. Species differences in the binding characteristics of [125I]IRL-1620, a potent agonist specific for endothelin-B receptors. J Pharmacol Exp Ther. 1994 Jan;268(1):202–207. [PubMed] [Google Scholar]
  21. Saeki T., Ihara M., Fukuroda T., Yamagiwa M., Yano M. [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity. Biochem Biophys Res Commun. 1991 Aug 30;179(1):286–292. doi: 10.1016/0006-291x(91)91367-l. [DOI] [PubMed] [Google Scholar]
  22. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  23. Schvartz I., Ittoop O., Hazum E. Direct evidence for multiple endothelin receptors. Biochemistry. 1991 May 28;30(21):5325–5327. doi: 10.1021/bi00235a028. [DOI] [PubMed] [Google Scholar]
  24. Supattapone S., Simpson A. W., Ashley C. C. Free calcium rise and mitogenesis in glial cells caused by endothelin. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1115–1122. doi: 10.1016/0006-291x(89)92718-6. [DOI] [PubMed] [Google Scholar]
  25. Tanaka T., Tsukuda E., Nozawa M., Nonaka H., Ohno T., Kase H., Yamada K., Matsuda Y. RES-701-1, a novel, potent, endothelin type B receptor-selective antagonist of microbial origin. Mol Pharmacol. 1994 Apr;45(4):724–730. [PubMed] [Google Scholar]
  26. Warner T. D., Allcock G. H., Corder R., Vane J. R. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993 Oct;110(2):777–782. doi: 10.1111/j.1476-5381.1993.tb13879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Warner T. D., Allcock G. H., Mickley E. J., Corder R., Vane J. R. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S117–S120. doi: 10.1097/00005344-199322008-00032. [DOI] [PubMed] [Google Scholar]
  28. Widdowson P. S., Simpson M. G., Wyatt I., Lock E. A. [125I]endothelin binding in rat cerebellum is increased following L-2-chloropropionic-acid-induced granule cell necrosis. Peptides. 1995;16(5):897–902. doi: 10.1016/0196-9781(95)00050-t. [DOI] [PubMed] [Google Scholar]
  29. Williams D. L., Jr, Jones K. L., Pettibone D. J., Lis E. V., Clineschmidt B. V. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun. 1991 Mar 15;175(2):556–561. doi: 10.1016/0006-291x(91)91601-8. [DOI] [PubMed] [Google Scholar]
  30. Yamamoto T., Shimoyama N., Asano H., Mizuguchi T. Analysis of the role of endothelin-A and endothelin-B receptors on nociceptive information transmission in the spinal cord with FR139317, an endothelin-A receptor antagonist, and sarafotoxin S6c, an endothelin-B receptor agonist. J Pharmacol Exp Ther. 1994 Oct;271(1):156–163. [PubMed] [Google Scholar]
  31. Yanagisawa M., Inoue A., Ishikawa T., Kasuya Y., Kimura S., Kumagaye S., Nakajima K., Watanabe T. X., Sakakibara S., Goto K. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6964–6967. doi: 10.1073/pnas.85.18.6964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yanagisawa M., Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol Sci. 1989 Sep;10(9):374–378. doi: 10.1016/0165-6147(89)90011-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES